Intellia's CRISPR Treatment Approaches Key Phase 3 Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NTLA?
Source: stocktwits
- Clinical Trial Progress: Intellia Therapeutics' Haelo Phase 3 trial represents the first late-stage test of an in-vivo CRISPR gene-editing treatment, with earlier mid-stage studies showing a 96% reduction in monthly attack rates and 97% of patients attack-free for up to three years; if confirmed, Lonvo-z could become the first one-time treatment to replace chronic preventive therapy.
- FDA Regulatory Update: The FDA recently lifted clinical holds on two Phase 3 trials of Nex-z, allowing enrollment to resume after improved safety measures were introduced, indicating a more favorable regulatory environment that could facilitate further advancements in gene-editing therapies.
- Investor Sentiment Surge: Ahead of the upcoming Haelo trial results, Intellia's shares surged 35% overnight, with retail sentiment on Stocktwits reaching a record 98/100, reflecting strong market confidence in the company's future prospects.
- Market Performance Review: Despite a 9% decline in NTLA stock last week, it has risen 67% over the past year, demonstrating sustained investor interest and trust in its gene-editing technology, particularly in light of the imminent key data release.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 15.870
Low
4.00
Averages
16.50
High
54.00
Current: 15.870
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Announces First Phase 3 Data for CRISPR Gene Editing Candidate
- Clinical Data Release: Intellia Therapeutics is set to announce topline data from its global Phase 3 HAELO trial for lonvoguran ziclumeran (lonvo-z) on April 27, 2026, marking a significant advancement for CRISPR gene editing in clinical applications.
- Webcast Announcement: The company will host a webcast at 8:00 a.m. ET on the same day to discuss the clinical data, which is expected to attract significant attention from investors and the medical community, enhancing the company's visibility in the biopharmaceutical sector.
- Commitment to Innovation: Intellia aims to transform the lives of patients with severe diseases through CRISPR gene editing and other core technologies, a mission that is likely to drive long-term growth in the biopharmaceutical industry.
- Market Potential: Given the rising demand for treatments for genetic disorders, successful clinical trial results for lonvo-z could open new market opportunities for Intellia, strengthening its competitive position in the biopharmaceutical market.
See More
Intellia's CRISPR Treatment Approaches Key Phase 3 Trial Results
- Clinical Trial Progress: Intellia Therapeutics' Haelo Phase 3 trial represents the first late-stage test of an in-vivo CRISPR gene-editing treatment, with earlier mid-stage studies showing a 96% reduction in monthly attack rates and 97% of patients attack-free for up to three years; if confirmed, Lonvo-z could become the first one-time treatment to replace chronic preventive therapy.
- FDA Regulatory Update: The FDA recently lifted clinical holds on two Phase 3 trials of Nex-z, allowing enrollment to resume after improved safety measures were introduced, indicating a more favorable regulatory environment that could facilitate further advancements in gene-editing therapies.
- Investor Sentiment Surge: Ahead of the upcoming Haelo trial results, Intellia's shares surged 35% overnight, with retail sentiment on Stocktwits reaching a record 98/100, reflecting strong market confidence in the company's future prospects.
- Market Performance Review: Despite a 9% decline in NTLA stock last week, it has risen 67% over the past year, demonstrating sustained investor interest and trust in its gene-editing technology, particularly in light of the imminent key data release.
See More
US Stock Futures Decline Amid Oil Price Surge
- US Futures Movement: As of 8:02 PM ET, Dow futures fell 0.22%, S&P 500 futures dropped 0.18%, and Nasdaq 100 futures declined 0.12%, indicating investor concerns over stalled negotiations with Iran, which may impact market confidence.
- Last Week's Market Performance: On Friday, the S&P 500 rose 0.80% to close at 7,165.08, and the Nasdaq Composite increased by 1.63% to 24,836.60, while the Dow Jones Industrial Average fell 0.16%, highlighting a mixed market trend that investors should monitor closely.
- Oil Price Surge: Brent crude futures increased by over 2% to $107.52 per barrel, while WTI crude futures also gained about 2%, trading at $96.29 per barrel, reflecting optimistic market expectations for energy demand that could influence related stocks.
- Market Sentiment Analysis: Retail sentiment on Stocktwits showed SPY in 'neutral' territory, while QQQ and DIA were in 'bearish' territory, indicating a cautious investor outlook on future market movements that may affect short-term trading strategies.
See More
Intellia to Release HAELO Trial Results in April 2026
- Clinical Milestone: Intellia Therapeutics is set to release topline results from its global Phase 3 HAELO clinical trial on April 27, 2026, marking the world's first Phase 3 readout for an in vivo CRISPR gene-editing candidate, potentially offering new treatment options for rare disease patients.
- Treatment Objective: The HAELO study aims to evaluate the efficacy of Lonvoguran ziclumeran as a one-time in vivo CRISPR therapy, targeting a reduction in the frequency and severity of hereditary angioedema (HAE) attacks, thereby addressing the underlying genetic cause and meeting patients' urgent need for long-term prevention.
- Market Reaction: On April 24, 2026, NTLA stock closed at $13.63, down 14.11% from the previous trading day, but surged 19.27% in after-hours trading to $16.26, reflecting positive market sentiment ahead of the upcoming clinical data release.
- Company Strategy: Intellia is focused on developing therapies that directly edit disease-causing genes within the body, and the results from the HAELO trial will provide crucial support for its broader mission, reinforcing its leadership position in the gene-editing sector.
See More
Intellia to Release Clinical Data for Lonvoguran Ziclumeran Therapy
- Clinical Data Release: Intellia Therapeutics is set to announce clinical data for its experimental therapy lonvoguran ziclumeran on Monday, which has already led to a 22% after-hours stock surge on Friday, indicating strong market anticipation.
- FDA Application Plans: Should the phase three trial data be supportive, Intellia plans to submit an application to the U.S. FDA for therapy approval in the second half of 2026, with a launch anticipated in the first half of 2027, showcasing the company's confidence in future market potential.
- Patient Recruitment Ahead of Schedule: The company completed enrollment of 80 patients for its global study in September 2025, ahead of schedule, which could expedite the product's path to market and enhance investor confidence.
- Positive Market Sentiment: Retail sentiment around NTLA on Stocktwits remains in the 'extremely bullish' territory, with message volume rising from 'high' to 'extremely high', reflecting strong investor interest in the upcoming data announcement.
See More
Analysis of Investment Prospects in Healthcare Stocks
- Animal Health Leader: Zoetis has faced challenges over the past two years, including increased competition and scrutiny over drug side effects; however, its strong market position and the potential market for untreated dogs make it attractive for long-term investors, with expectations to continue launching new products to meet rising pet spending.
- New Drug Development Potential: BioNTech has underperformed in the coronavirus vaccine market, but its impressive pipeline with over 25 clinical trials in oncology, particularly the promising BNT327 developed with Bristol Myers Squibb, could set new standards of care across multiple indications, with significant clinical and regulatory progress expected over the next five years.
- Gene Editing Risks: Intellia Therapeutics' lonvo-z and nex-z are undergoing phase 3 studies but face uncertainty; despite the FDA lifting the hold on clinical trials, the high costs and complexities of gene editing treatments make steady revenue generation unlikely in the coming years, presenting substantial investment risks.
- Dividend Appeal: Zoetis has increased its dividends by 458% over the past decade, making it a top choice for income-seeking investors, reflecting its long-term investment value in the animal health market despite facing short-term challenges.
See More
Intellia Announces First Phase 3 Data for CRISPR Gene Editing Candidate
- Clinical Data Release: Intellia Therapeutics is set to announce topline data from its global Phase 3 HAELO trial for lonvoguran ziclumeran (lonvo-z) on April 27, 2026, marking a significant advancement for CRISPR gene editing in clinical applications.
- Webcast Announcement: The company will host a webcast at 8:00 a.m. ET on the same day to discuss the clinical data, which is expected to attract significant attention from investors and the medical community, enhancing the company's visibility in the biopharmaceutical sector.
- Commitment to Innovation: Intellia aims to transform the lives of patients with severe diseases through CRISPR gene editing and other core technologies, a mission that is likely to drive long-term growth in the biopharmaceutical industry.
- Market Potential: Given the rising demand for treatments for genetic disorders, successful clinical trial results for lonvo-z could open new market opportunities for Intellia, strengthening its competitive position in the biopharmaceutical market.
See More
Intellia's CRISPR Treatment Approaches Key Phase 3 Trial Results
- Clinical Trial Progress: Intellia Therapeutics' Haelo Phase 3 trial represents the first late-stage test of an in-vivo CRISPR gene-editing treatment, with earlier mid-stage studies showing a 96% reduction in monthly attack rates and 97% of patients attack-free for up to three years; if confirmed, Lonvo-z could become the first one-time treatment to replace chronic preventive therapy.
- FDA Regulatory Update: The FDA recently lifted clinical holds on two Phase 3 trials of Nex-z, allowing enrollment to resume after improved safety measures were introduced, indicating a more favorable regulatory environment that could facilitate further advancements in gene-editing therapies.
- Investor Sentiment Surge: Ahead of the upcoming Haelo trial results, Intellia's shares surged 35% overnight, with retail sentiment on Stocktwits reaching a record 98/100, reflecting strong market confidence in the company's future prospects.
- Market Performance Review: Despite a 9% decline in NTLA stock last week, it has risen 67% over the past year, demonstrating sustained investor interest and trust in its gene-editing technology, particularly in light of the imminent key data release.
See More
US Stock Futures Decline Amid Oil Price Surge
- US Futures Movement: As of 8:02 PM ET, Dow futures fell 0.22%, S&P 500 futures dropped 0.18%, and Nasdaq 100 futures declined 0.12%, indicating investor concerns over stalled negotiations with Iran, which may impact market confidence.
- Last Week's Market Performance: On Friday, the S&P 500 rose 0.80% to close at 7,165.08, and the Nasdaq Composite increased by 1.63% to 24,836.60, while the Dow Jones Industrial Average fell 0.16%, highlighting a mixed market trend that investors should monitor closely.
- Oil Price Surge: Brent crude futures increased by over 2% to $107.52 per barrel, while WTI crude futures also gained about 2%, trading at $96.29 per barrel, reflecting optimistic market expectations for energy demand that could influence related stocks.
- Market Sentiment Analysis: Retail sentiment on Stocktwits showed SPY in 'neutral' territory, while QQQ and DIA were in 'bearish' territory, indicating a cautious investor outlook on future market movements that may affect short-term trading strategies.
See More
Intellia to Release HAELO Trial Results in April 2026
- Clinical Milestone: Intellia Therapeutics is set to release topline results from its global Phase 3 HAELO clinical trial on April 27, 2026, marking the world's first Phase 3 readout for an in vivo CRISPR gene-editing candidate, potentially offering new treatment options for rare disease patients.
- Treatment Objective: The HAELO study aims to evaluate the efficacy of Lonvoguran ziclumeran as a one-time in vivo CRISPR therapy, targeting a reduction in the frequency and severity of hereditary angioedema (HAE) attacks, thereby addressing the underlying genetic cause and meeting patients' urgent need for long-term prevention.
- Market Reaction: On April 24, 2026, NTLA stock closed at $13.63, down 14.11% from the previous trading day, but surged 19.27% in after-hours trading to $16.26, reflecting positive market sentiment ahead of the upcoming clinical data release.
- Company Strategy: Intellia is focused on developing therapies that directly edit disease-causing genes within the body, and the results from the HAELO trial will provide crucial support for its broader mission, reinforcing its leadership position in the gene-editing sector.
See More
Intellia to Release Clinical Data for Lonvoguran Ziclumeran Therapy
- Clinical Data Release: Intellia Therapeutics is set to announce clinical data for its experimental therapy lonvoguran ziclumeran on Monday, which has already led to a 22% after-hours stock surge on Friday, indicating strong market anticipation.
- FDA Application Plans: Should the phase three trial data be supportive, Intellia plans to submit an application to the U.S. FDA for therapy approval in the second half of 2026, with a launch anticipated in the first half of 2027, showcasing the company's confidence in future market potential.
- Patient Recruitment Ahead of Schedule: The company completed enrollment of 80 patients for its global study in September 2025, ahead of schedule, which could expedite the product's path to market and enhance investor confidence.
- Positive Market Sentiment: Retail sentiment around NTLA on Stocktwits remains in the 'extremely bullish' territory, with message volume rising from 'high' to 'extremely high', reflecting strong investor interest in the upcoming data announcement.
See More
Analysis of Investment Prospects in Healthcare Stocks
- Animal Health Leader: Zoetis has faced challenges over the past two years, including increased competition and scrutiny over drug side effects; however, its strong market position and the potential market for untreated dogs make it attractive for long-term investors, with expectations to continue launching new products to meet rising pet spending.
- New Drug Development Potential: BioNTech has underperformed in the coronavirus vaccine market, but its impressive pipeline with over 25 clinical trials in oncology, particularly the promising BNT327 developed with Bristol Myers Squibb, could set new standards of care across multiple indications, with significant clinical and regulatory progress expected over the next five years.
- Gene Editing Risks: Intellia Therapeutics' lonvo-z and nex-z are undergoing phase 3 studies but face uncertainty; despite the FDA lifting the hold on clinical trials, the high costs and complexities of gene editing treatments make steady revenue generation unlikely in the coming years, presenting substantial investment risks.
- Dividend Appeal: Zoetis has increased its dividends by 458% over the past decade, making it a top choice for income-seeking investors, reflecting its long-term investment value in the animal health market despite facing short-term challenges.
See More
